Company intelligence / Profile preview

IDG-Accel China

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

IDG-Accel China is a prominent series of venture capital funds focused on the Chinese market, established through a partnership between IDG Capital and Accel Partners. The firm specializes in seed, startup, and growth-stage investments across various sectors, with a significant emphasis on healthcare, biotechnology, and information technology. Within the life sciences sector, IDG-Accel has been a major investor in companies such as CASI Pharmaceuticals (formerly EntreMed) and Hainan Shuangcheng Pharmaceuticals. The firm provides strategic support and capital to innovative companies in the Greater China region, leveraging its extensive network and industry expertise to drive growth and commercialization.

Industry: Investors

Partnerships

Accel PartnersCASI Pharmaceuticals

Beyond the preview

Go deeper on IDG-Accel China.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDG-Accel China.

Explore the full profile